Clinical Trial Update: Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC [Phase 1, Phase 2]

View source ↗

Summary

This document updates on an ongoing Phase 1/2 trial evaluating the combination of bevacizumab and pembrolizumab for platinum-resistant locally recurrent/metasta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)
• Pembrolizumab (Keytruda) (pembrolizumab)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Locally Recurrent Cancer, Metastatic Nasopharyngeal Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING